Antimalarial drug resistance and early drug discovery

Current Pharmaceutical Design

Volumn 19, Issue 2, 2013, Pages 270-281

  Garcia Bustos, Jose F ^a   Gamo, Francisco Javier ^b  

^a MONASH UNIVERSITY   (Australia)

^b GLAXOSMITHKLINE   (Spain)

Author keywords

Antimalarials; Artemisinins; Chloroquine; Drug discovery; Markers; Plasmodium falciparum; Plasmodium vivax; Resistance

Indexed keywords

ANTIMALARIAL AGENT; ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; BENFLUMETOL; CHLOROQUINE; CYTOCHROME B; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; ENDOPEROXIDE; FOLIC ACID ANTAGONIST; LACTATE DEHYDROGENASE; MEFLOQUINE; MOLECULAR MARKER; NAPHTHOQUINONE; PYRIMETHAMINE; QUININE; QUINOLINE; VERAPAMIL;

ANTIMALARIAL DRUG RESISTANCE; ANTIMALARIAL DRUG SUSCEPTIBILITY; DNA REPAIR; DNA SEQUENCE; GAMETOCYTE; GENE EXPRESSION; GENE MUTATION; GENE TRANSFER; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR MECHANICS; MONOTHERAPY; PHENOTYPE; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT FAILURE; TREATMENT RESPONSE;

EID: 84877931241     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804070357     Document Type: Review

References (190)

1. World Health Organization. Global report on antimalarial drug efficacy and drug resistance: 2000-2010. http://whqlibdoc.who.int/ publications/2010/9789241500470_eng pdf 2010.
2. Maguire JD, Sumawinata IW, Masbar S, et al. Chloroquineresistant Plasmodium malariae in south Sumatra, Indonesia. Lancet 2002; 360: 58-60.
3. Hyde JE. Drug-resistant malaria-an insight. FEBS J 2007; 274: 4688-98.
4. Muller IB, Hyde JE. Antimalarial drugs: modes of action and mechanisms of parasite resistance. Future Microbiol 2010; 5: 1857-73.
5. Petersen I, Eastman R, Lanzer M. Drug-resistant malaria: molecular mechanisms and implications for public health. FEBS Lett 2011; 585: 1551-62.
6. Noedl H. The need for new antimalarial drugs less prone to resistance. Curr Pharm Des 2012; In press.
7. Sullivan DJ. Plasmodium drug targets outside the genetic control of the parasite. Curr Pharm Des 2012; In press.
8. Bacon DJ, Tang D, Salas C, et al. Effects of point mutations in Plasmodium falciparum dihydrofolate reductase and dihydropterate synthase genes on clinical outcomes and in vitro susceptibility to sulfadoxine and pyrimethamine. PLoS One 2009; 4: e6762.
9. Menard D, Yapou F, Manirakiza A, Djalle D, Matsika-Claquin MD, Talarmin A. Polymorphisms in pfcrt, pfmdr1, dhfr genes and in vitro responses to antimalarials in Plasmodium falciparum isolates from Bangui, Central African Republic. Am J Trop Med Hyg 2006; 75: 381-7.
10. Musset L, Le BJ, Clain J. Parallel evolution of adaptive mutations in Plasmodium falciparum mitochondrial DNA during atovaquoneproguanil treatment. Mol Biol Evol 2007; 24: 1582-5.
11. Picot S, Olliaro P, de MF, Bienvenu AL, Price RN, Ringwald P. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J 2009; 8: 89.
12. Sutherland CJ, Laundy M, Price N, et al. Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquoneproguanil. Malar J 2008; 7: 240.
13. Vaidya AB, Mather MW. Atovaquone resistance in malaria parasites. Drug Resist Updat 2000; 3: 283-7.
14. Andriantsoanirina V, Ratsimbasoa A, Bouchier C, et al. Chloroquine clinical failures in P. falciparum malaria are associated with mutant Pfmdr-1, not Pfcrt in Madagascar. PLoS One 2010; 5: e13281.
15. Chandra R, Tripathi LM, Saxena JK, Puri SK. Implication of intracellular glutathione and its related enzymes on resistance of malaria parasites to the antimalarial drug arteether. Parasitol Int 2011; 60: 97-100.
16. Deplaine G, Lavazec C, Bischoff E, et al. Artesunate tolerance in transgenic Plasmodium falciparum parasites overexpressing a tryptophan-rich protein. Antimicrob Agents Chemother 2011; 55: 2576-84.
17. Hunt P, Afonso A, Creasey A, et al. Gene encoding a deubiquitinating enzyme is mutated in artesunate-and chloroquine-resistant rodent malaria parasites. Mol Microbiol 2007; 65: 27-40.
18. Valderramos SG, Scanfeld D, Uhlemann AC, Fidock DA, Krishna S. Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance. Antimicrob Agents Chemother 2010; 54: 3842-52.
19. Valderramos SG, Valderramos JC, Musset L, et al. Identification of a mutant PfCRT-mediated chloroquine tolerance phenotype in Plasmodium falciparum. PLoS Pathog 2010; 6: e1000887.
20. Zakeri S, Afsharpad M, Kazemzadeh T, Mehdizadeh K, Shabani A, Djadid ND. Association of pfcrt but not pfmdr1 alleles with chloroquine resistance in Iranian isolates of Plasmodium falciparum. Am J Trop Med Hyg 2008; 78: 633-40.
21. Antao T, Hastings IM. Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria. Proc Biol Sci 2011; 278: 1705-12.
22. White NJ. The assessment of antimalarial drug efficacy. Trends Parasitol 2002; 18: 458-64.
23. Tuomanen E, Durack DT, Tomasz A. Antibiotic tolerance among clinical isolates of bacteria. Antimicrob Agents Chemother 1986; 30: 521-7.
24. Hastings IM, Watkins WM. Tolerance is the key to understanding antimalarial drug resistance. Trends Parasitol 2006; 22: 71-7.
25. Paget-McNicol S, Saul A. Mutation rates in the dihydrofolate reductase gene of Plasmodium falciparum. Parasitology 2001; 122: 497-505.
26. Rathod PK, McErlean T, Lee PC. Variations in frequencies of drug resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 1997; 94: 9389-93.
27. Cowman AF, Galatis D, Thompson JK. Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc Natl Acad Sci U S A 1994; 91: 1143-7.
28. Peel SA, Bright P, Yount B, Handy J, Baric RS. A strong association between mefloquine and halofantrine resistance and amplification, overexpression, and mutation in the P-glycoprotein gene homolog (pfmdr) of Plasmodium falciparum in vitro. Am J Trop Med Hyg 1994; 51: 648-58.
29. Hastings IM, Korenromp EL, Bloland PB. The anatomy of a malaria disaster: drug policy choice and mortality in African children. Lancet Infect Dis 2007; 7: 739-48.
30. Sama W, Owusu-Agyei S, Felger I, Vounatsou P, Smith T. An immigration-death model to estimate the duration of malaria infection when detectability of the parasite is imperfect. Stat Med 2005; 24: 3269-88.
31. Huijben S, Nelson WA, Wargo AR, Sim DG, Drew DR, Read AF. Chemotherapy, within-host ecology and the fitness of drugresistant malaria parasites. Evolution 2010; 64: 2952-68.
32. Wargo AR, Huijben S, de Roode JC, Shepherd J, Read AF. Competitive release and facilitation of drug-resistant parasites after therapeutic chemotherapy in a rodent malaria model. Proc Natl Acad Sci U S A 2007; 104: 19914-9.
33. Huijben S, Sim DG, Nelson WA, Read AF. The fitness of drugresistant malaria parasites in a rodent model: multiplicity of infection. J Evol Biol 2011; 24: 2410-22.
34. Babiker HA, Hastings IM, Swedberg G. Impaired fitness of drugresistant malaria parasites: evidence and implication on drugdeployment policies. Expert Rev Anti Infect Ther 2009; 7: 581-93.
35. Peters JM, Chen N, Gatton M, et al. Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness in Plasmodium falciparum. Antimicrob Agents Chemother 2002; 46: 2435-41.
36. Sandefur CI, Wooden JM, Quaye IK, Sirawaraporn W, Sibley CH. Pyrimethamine-resistant dihydrofolate reductase enzymes of Plasmodium falciparum are not enzymatically compromised in vitro. Mol Biochem Parasitol 2007; 154: 1-5.
37. Jiang H, Patel JJ, Yi M, et al. Genome-wide compensatory changes accompany drug-selected mutations in the Plasmodium falciparum crt gene. PLoS One 2008; 3: e2484.
38. Walliker D, Hunt P, Babiker H. Fitness of drug-resistant malaria parasites. Acta Trop 2005; 94: 251-9.
39. Laufer MK, Takala-Harrison S, Dzinjalamala FK, Stine OC, Taylor TE, Plowe CV. Return of chloroquine-susceptible falciparum malaria in Malawi was a reexpansion of diverse susceptible parasites. J Infect Dis 2010; 202: 801-8.
40. Noranate N, Durand R, Tall A, et al. Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use. PLoS One 2007; 2: e139.
41. Yang Z, Zhang Z, Sun X, et al. Molecular analysis of chloroquine resistance in Plasmodium falciparum in Yunnan Province, China. Trop Med Int Health 2007; 12: 1051-60.
42. Silva RF, Mendonca SC, Carvalho LM, et al. Pervasive sign epistasis between conjugative plasmids and drug-resistance chromosomal mutations. PLoS Genet 2011; 7: e1002181.
43. Bethke L, Thomas S, Walker K, Lakhia R, Rangarajan R, Wirth D. The role of DNA mismatch repair in generating genetic diversity and drug resistance in malaria parasites. Mol Biochem Parasitol 2007; 155: 18-25.
44. Castellini MA, Buguliskis JS, Casta LJ, et al. Malaria drug resistance is associated with defective DNA mismatch repair. Mol Biochem Parasitol 2011; 177: 143-7.
45. Trotta RF, Brown ML, Terrell JC, Geyer JA. Defective DNA repair as a potential mechanism for the rapid development of drug resistance in Plasmodium falciparum. Biochemistry 2004; 43: 4885-91.
46. Gassis S, Rathod PK. Frequency of drug resistance in Plasmodium falciparum: a nonsynergistic combination of 5-fluoroorotate and atovaquone suppresses in vitro resistance. Antimicrob Agents Chemother 1996; 40: 914-9.
47. Price R, Nosten F, Simpson JA, et al. Risk factors for gametocyte carriage in uncomplicated falciparum malaria. Am J Trop Med Hyg 1999; 60: 1019-23.
48. Handunnetti SM, Gunewardena DM, Pathirana PP, Ekanayake K, Weerasinghe S, Mendis KN. Features of recrudescent chloroquineresistant Plasmodium falciparum infections confer a survival ad vantage on parasites and have implications for disease control. Trans R Soc Trop Med Hyg 1996; 90: 563-7.
49. Robert V, Wono-Ambene HP, Le Hesran JY, Trape JF. Gametocytemia and infectivity to mosquitoes of patients with uncomplicated Plasmodium falciparum malaria attacks treated with chloroquine or sulfadoxine plus pyrimethamine. Am J Trop Med Hyg 2000; 62: 210-6.
50. Hallett RL, Sutherland CJ, Alexander N, et al. Combination therapy counteracts the enhanced transmission of drug-resistant malaria parasites to mosquitoes. Antimicrob Agents Chemother 2004; 48: 3940-3.
51. Hastings IM. Gametocytocidal activity in antimalarial drugs speeds the spread of drug resistance. J Infect Dis 2011; 203: 228-36.
52. Hastings IM. Gametocytocidal activity in antimalarial drugs speeds the spread of drug resistance. Trop Med Int Health 2006; 11: 1206-17.
53. Read AF, Day T, Huijben S. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. Proc Natl Acad Sci U S A 2011; 108 Suppl 2: 10871-7.
54. Fidock DA, Eastman RT, Ward SA, Meshnick SR. Recent highlights in antimalarial drug resistance and chemotherapy research. Trends Parasitol 2008; 24: 537-44.
55. Valderramos SG, Fidock DA. Transporters involved in resistance to antimalarial drugs. Trends Pharmacol Sci 2006; 27: 594-601.
56. Fidock DA, Nomura T, Talley AK, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell 2000; 6: 861-71.
57. Su X, Kirkman LA, Fujioka H, Wellems TE. Complex polymorphisms in an approximately 330 kDa protein are linked to chloroquine-resistant P. falciparum in Southeast Asia and Africa. Cell 1997; 91: 593-603.
58. Bray PG, Mungthin M, Hastings IM, et al. PfCRT and the transvacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX. Mol Microbiol 2006; 62: 238-51.
59. Chinappi M, Via A, Marcatili P, Tramontano A. On the mechanism of chloroquine resistance in Plasmodium falciparum. PLoS One 2010; 5: e14064.
60. Lakshmanan V, Bray PG, Verdier-Pinard D, et al. A critical role for PfCRT K76T in Plasmodium falciparum verapamil-reversible chloroquine resistance. EMBO J 2005; 24: 2294-305.
61. Cabrera M, Paguio MF, Xie C, Roepe PD. Reduced digestive vacuolar accumulation of chloroquine is not linked to resistance to chloroquine toxicity. Biochemistry 2009; 48: 11152-4.
62. Lehane AM, van Schalkwyk DA, Valderramos SG, Fidock DA, Kirk K. Differential drug efflux or accumulation does not explain variation in the chloroquine response of Plasmodium falciparum strains expressing the same isoform of mutant PfCRT. Antimicrob Agents Chemother 2011; 55: 2310-8.
63. Das MK, Lumb V, Mittra P, Singh SS, Dash AP, Sharma YD. High chloroquine treatment failure rates and predominance of mutant genotypes associated with chloroquine and antifolate resistance among falciparum malaria patients from the island of Car Nicobar, India. J Antimicrob Chemother 2010; 65: 1258-61.
64. Hatabu T, Iwagami M, Kawazu S, et al. Association of molecular markers in Plasmodium falciparum crt and mdr1 with in vitro chloroquine resistance: a Philippine study. Parasitol Int 2009; 58: 166-70.
65. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985; 316: 817-9.
66. Barnes DA, Foote SJ, Galatis D, Kemp DJ, Cowman AF. Selection for high-level chloroquine resistance results in deamplification of the pfmdr1 gene and increased sensitivity to mefloquine in Plasmodium falciparum. EMBO J 1992; 11: 3067-75.
67. Sidhu AB, Uhlemann AC, Valderramos SG, Valderramos JC, Krishna S, Fidock DA. Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin. J Infect Dis 2006; 194: 528-35.
68. Duraisingh MT, Cowman AF. Contribution of the pfmdr1 gene to antimalarial drug-resistance. Acta Trop 2005; 94: 181-90.
69. Chen N, Russell B, Fowler E, Peters J, Cheng Q. Levels of chloroquine resistance in Plasmodium falciparum are determined by loci other than pfcrt and pfmdr1. J Infect Dis 2002; 185: 405-7.
70. Raj DK, Mu J, Jiang H, et al. Disruption of a Plasmodium falciparum multidrug resistance-associated protein (PfMRP) alters its fitness and transport of antimalarial drugs and glutathione. J Biol Chem 2009; 284: 7687-96.
71. Koenderink JB, Kavishe RA, Rijpma SR, Russel FG. The ABCs of multidrug resistance in malaria. Trends Parasitol 2010; 26: 440-6.
72. Sanchez CP, Dave A, Stein WD, Lanzer M. Transporters as mediators of drug resistance in Plasmodium falciparum. Int J Parasitol 2010; 40: 1109-18.
73. Vaidya AB, Akella R, Suplick K. Sequences similar to genes for two mitochondrial proteins and portions of ribosomal RNA in tandemly arrayed 6-kilobase-pair DNA of a malarial parasite. Mol Biochem Parasitol 1989; 35: 97-107.
74. Fry M, Pudney M. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4'-chlorophenyl) cyclohexyl]-3-hydroxy-1,4-naphthoquinone (566C80). Biochem Pharmacol 1992; 43: 1545-53.
75. Painter HJ, Morrisey JM, Mather MW, Vaidya AB. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature 2007; 446: 88-91.
76. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drugbinding site. Antimicrob Agents Chemother 2000; 44: 2100-8.
77. Mather MW, Darrouzet E, Valkova-Valchanova, et al. Uncovering the molecular mode of action of the antimalarial drug atovaquone using a bacterial system. J Biol Chem 2005; 280: 27458-65.
78. Fisher N, Meunier B. Re-examination of inhibitor resistance conferred by Qo-site mutations in cytochrome b using yeast as a model system. Pest Manag Sci 2005; 61: 973-8.
79. Kessl JJ, Ha KH, Merritt AK, et al. Cytochrome b mutations that modify the ubiquinol-binding pocket of the cytochrome bc1 complex and confer anti-malarial drug resistance in Saccharomyces cerevisiae. J Biol Chem 2005; 280: 17142-8.
80. Afonso A, Neto Z, Castro H, et al. Plasmodium chabaudi chabaudi malaria parasites can develop stable resistance to atovaquone with a mutation in the cytochrome b gene. Malar J 2010; 9: 135.
81. Syafruddin D, Siregar JE, Marzuki S. Mutations in the cytochrome b gene of Plasmodium berghei conferring resistance to atovaquone. Mol Biochem Parasitol 1999; 104: 185-94.
82. Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, Vaidya AB. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol Microbiol 1999; 33: 704-11.
83. Perry TL, Pandey P, Grant JM, Kain KC. Severe atovaquoneresistant Plasmodium falciparum malaria in a Canadian traveller returned from the Indian subcontinent. Open Med 2009; 3: e10-e16.
84. Musset L, Bouchaud O, Matheron S, Massias L, Le BJ. Clinical atovaquone-proguanil resistance of Plasmodium falciparum associated with cytochrome b codon 268 mutations. Microbes Infect 2006; 8: 2599-604.
85. Wichmann O, Muehlen M, Gruss H, Mockenhaupt FP, Suttorp N, Jelinek T. Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Malar J 2004; 3: 14.
86. Kain KC. Current status and replies to frequently posed questions on atovaquone plus proguanil (Malarone) for the prevention of malaria. BioDrugs 2003; 17 Suppl 1: 23-8.
87. Naoshima-Ishibashi Y, Iwagami M, Kawazu S, Looareesuwan S, Kano S. Analyses of cytochrome b mutations in Plasmodium falciparum isolates in Thai-Myanmar border. Travel Med Infect Dis 2007; 5: 132-4.
88. Ekala MT, Khim N, Legrand E, et al. Sequence analysis of Plasmodium falciparum cytochrome b in multiple geographic sites. Malar J 2007; 6: 164.
89. Khositnithikul R, Tan-Ariya P, Mungthin M. In vitro atovaquone/ proguanil susceptibility and characterization of the cytochrome b gene of Plasmodium falciparum from different endemic regions of Thailand. Malar J 2008; 7: 23.
90. Sirawaraporn W. Dihydrofolate reductase and antifolate resistance in malaria. Drug Resist Updat 1998; 1: 397-406.
91. Bzik DJ, Li WB, Horii T, Inselburg J. Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc Natl Acad Sci U S A 1987; 84: 8360-4.
92. Gutteridge WE, Trigg PI. Action of pyrimethamine and related drugs against Plasmodium knowlesi in vitro. Parasitology 1971; 62: 431-44.
93. Fidock DA, Nomura T, Wellems TE. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Mol Pharmacol 1998; 54: 1140-7.
94. Zhang K, Rathod PK. Divergent regulation of dihydrofolate reductase between malaria parasite and human host. Science 2002; 296: 545-7.
95. O'Neil MT, Korsinczky ML, Gresty KJ, Auliff A, Cheng Q. A novel Plasmodium falciparum expression system for assessing antifolate resistance caused by mutant P. vivax dihydrofolate reductase-thymidylate synthase. J Infect Dis 2007; 196: 467-74.
96. Bunyarataphan S, Leartsakulpanich U, Taweechai S, Tarnchompoo B, Kamchonwongpaisan S, Yuthavong Y. Evaluation of the activities of pyrimethamine analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial complementation assays. Antimicrob Agents Chemother 2006; 50: 3631-7.
97. Andriantsoanirina V, Bouchier C, Tichit M, et al. Origins of the recent emergence of Plasmodium falciparum pyrimethamine resistance alleles in Madagascar. Antimicrob Agents Chemother 2010; 54: 2323-9.
98. Galindo JA, Cristiano FA, Knudson A, Nicholls RS, Guerra AP. [Point mutations in dihydrofolate reductase and dihydropteroate synthase genes of Plasmodium falciparum from three endemic malaria regions in Colombia]. Biomedica 2010; 30: 56-64.
99. Mombo-Ngoma G, Oyakhirome S, Ord R, Gabor JJ, Greutelaers KC, Profanter K, et al. High prevalence of dhfr triple mutant and correlation with high rates of sulphadoxine-pyrimethamine treatment failures in vivo in Gabonese children. Malar J 2011; 10: 123.
100. Spalding MD, Eyase FL, Akala HM, et al. Increased prevalence of the pfdhfr/phdhps quintuple mutant and rapid emergence of pfdhps resistance mutations at codons 581 and 613 in Kisumu, Kenya. Malar J 2010; 9: 338.
101. Sridaran S, McClintock SK, Syphard LM, Herman KM, Barnwell JW, Udhayakumar V. Anti-folate drug resistance in Africa: metaanalysis of reported dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium falciparum parasite populations. Malar J 2010; 9: 247.
102. Peterson DS, Walliker D, Wellems TE. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc Natl Acad Sci U S A 1988; 85: 9114-8.
103. Sirawaraporn W, Sathitkul T, Sirawaraporn R, Yuthavong Y, Santi DV. Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc Natl Acad Sci U S A 1997; 94: 1124-9.
104. Lumb V, Das MK, Mittra P, et al. Emergence of an unusual sulfadoxine-pyrimethamine resistance pattern and a novel K540N mutation in dihydropteroate synthetase in Plasmodium falciparum isolates obtained from Car Nicobar Island, India, after the 2004 Tsunami. J Infect Dis 2009; 199: 1064-73.
105. Plowe CV, Cortese JF, Djimde A, et al. Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J Infect Dis 1997; 176: 1590-6.
106. Wang P, Brooks DR, Sims PF, Hyde JE. A mutation-specific PCR system to detect sequence variation in the dihydropteroate synthetase gene of Plasmodium falciparum. Mol Biochem Parasitol 1995; 71: 115-25.
107. Triglia T, Menting JG, Wilson C, Cowman AF. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 1997; 94: 13944-9.
108. Corredor V, Murillo C, Echeverry DF, et al. Origin and dissemination across the Colombian Andes mountain range of sulfadoxinepyrimethamine resistance in Plasmodium falciparum. Antimicrob Agents Chemother 2010; 54: 3121-5.
109. Marfurt J, Muller I, Sie A, et al. The usefulness of twenty-four molecular markers in predicting treatment outcome with combination therapy of amodiaquine plus sulphadoxine-pyrimethamine against falciparum malaria in Papua New Guinea. Malar J 2008; 7: 61.
110. Raman J, Little F, Roper C, et al. Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique. Am J Trop Med Hyg 2010; 82: 788-94.
111. Mayor A, Serra-Casas E, Sanz S, et al. Molecular markers of resistance to sulfadoxine-pyrimethamine during intermittent preventive treatment for malaria in Mozambican infants. J Infect Dis 2008; 197: 1737-42.
112. Alam MT, de Souza DK, Vinayak S, et al. Selective sweeps and genetic lineages of Plasmodium falciparum drug-resistant alleles in Ghana. J Infect Dis 2011; 203: 220-7.
113. Lumb V, Das MK, Singh N, Dev V, Khan W, Sharma YD. Multiple origins of Plasmodium falciparum dihydropteroate synthetase mutant alleles associated with sulfadoxine resistance in India. Antimicrob Agents Chemother 2011; 55: 2813-7.
114. Ranjitkar S, Schousboe ML, Thomsen TT, et al. Prevalence of molecular markers of anti-malarial drug resistance in Plasmodium vivax and Plasmodium falciparum in two districts of Nepal. Malar J 2011; 10: 75.
115. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009; 361: 455-67.
116. Lin JT, Juliano JJ, Wongsrichanalai C. Drug-Resistant Malaria: The Era of ACT. Curr Infect Dis Rep 2010; 12: 165-73.
117. White NJ. Qinghaosu (artemisinin): the price of success. Science 2008; 320: 330-4.
118. Anderson TJ, Nair S, Nkhoma S, et al. High heritability of malaria parasite clearance rate indicates a genetic basis for artemisinin resistance in western Cambodia. J Infect Dis 2010; 201: 1326-30.
119. Ding XC, Beck HP, Raso G. Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets. Trends Parasitol 2011; 27: 73-81.
120. O'Neill PM, Barton VE, Ward SA. The molecular mechanism of action of artemisinin--the debate continues. Molecules 2010; 15: 1705-21.
121. Bousejra-El GF, Wong MH, Amewu RK, et al. Comparison of the reactivity of antimalarial 1,2,4,5-tetraoxanes with 1,2,4-trioxolanes in the presence of ferrous iron salts, heme, and ferrous iron salts/phosphatidylcholine. J Med Chem 2011; 54: 6443-55.
122. Fugi MA, Wittlin S, Dong Y, Vennerstrom JL. Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals. Antimicrob Agents Chemother 2010; 54: 1042-6.
123. Nosoongnoen W, Pratuangdejkul J, Sathirakul K, et al. Elucidation of the natural artemisinin decomposition route upon iron interaction: a fine electronic redistribution promotes reactivity. Phys Chem Chem Phys 2008; 10: 5083-93.
124. Mercer AE, Copple IM, Maggs JL, O'Neill PM, Park BK. The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J Biol Chem 2011; 286: 987-96.
125. Wang J, Huang L, Li J, et al. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One 2010; 5: e9582.
126. Klonis N, Crespo-Ortiz MP, Bottova I, et al. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci U S A 2011; 108: 11405-10.
127. Meunier B, Robert A. Heme as trigger and target for trioxanecontaining antimalarial drugs. Acc Chem Res 2010; 43: 1444-51.
128. Plasmodium Genomic Database. PlasmoDB, http://plasmodb.org/plasmo 2012.
129. Hunt P, Martinelli A, Modrzynska K, et al. Experimental evolution, genetic analysis and genome re-sequencing reveal the mutation conferring artemisinin resistance in an isogenic lineage of malaria parasites. BMC Genomics 2010; 11: 499.
130. Eckstein-Ludwig U, Webb RJ, Van G, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature 2003; 424: 957-61.
131. Tahar R, Ringwald P, Basco LK. Molecular epidemiology of malaria in Cameroon. XXVIII. In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum and sequence analysis of the P. falciparum ATPase 6 gene. Am J Trop Med Hyg 2009; 81: 13-8.
132. Kwansa-Bentum B, Ayi I, Suzuki T, et al. Plasmodium falciparum isolates from southern Ghana exhibit polymorphisms in the SERCA-type PfATPase6 though sensitive to artesunate in vitro. Malar J 2011; 10: 187.
133. Chavchich M, Gerena L, Peters J, Chen N, Cheng Q, Kyle DE. Role of pfmdr1 amplification and expression in induction of resis tance to artemisinin derivatives in Plasmodium falciparum. Antimicrob Agents Chemother 2010; 54: 2455-64.
134. Lim P, Alker AP, Khim N, et al. Pfmdr1 copy number and arteminisin derivatives combination therapy failure in falciparum malaria in Cambodia. Malar J 2009; 8: 11.
135. Veiga MI, Ferreira PE, Jornhagen L, et al. Novel polymorphisms in Plasmodium falciparum ABC transporter genes are associated with major ACT antimalarial drug resistance. PLoS One 2011; 6: e20212.
136. Imwong M, Dondorp AM, Nosten F, et al. Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob Agents Chemother 2010; 54: 2886-92.
137. Lacrue AN, Scheel M, Kennedy K, Kumar N, Kyle DE. Effects of Artesunate on Parasite Recrudescence and Dormancy in the Rodent Malaria Model Plasmodium vinckei. PLoS One 2011; 6: e26689.
138. Teuscher F, Chen N, Kyle DE, Gatton ML, Cheng Q. Phenotypic changes in artemisinin resistant Plasmodium falciparum lines in vitro: evidence for decreased sensitivity to dormancy and growth inhibition. Antimicrob Agents Chemother 2011.
139. Mok S, Imwong M, Mackinnon MJ, et al. Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription. BMC Genomics 2011; 12: 391.
140. Chauhan SS, Sharma M, Chauhan PM. Trioxaquines: hybrid molecules for the treatment of malaria. Drug News Perspect 2010; 23: 632-46.
141. Charman SA, Rbe-Barnes S, Bathurst IC, et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci U S A 2011; 108: 4400-5.
142. Price RN, Douglas NM, Anstey NM. New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Curr Opin Infect Dis 2009; 22: 430-5.
143. Carlton JM, Sina BJ, Adams JH. Why is Plasmodium vivax a neglected tropical disease? PLoS Negl Trop Dis 2011; 5: e1160.
144. Acharya P, Pallavi R, Chandran S, et al. Clinical Proteomics of the Neglected Human Malarial Parasite Plasmodium vivax. PLoS One 2011; 6: e26623.
145. Wernsdorfer WH, Tasanor O, Wernsdorfer G. In vitro drug sensitivity testing in Plasmodium vivax. Wien Klin Wochenschr 2008; 120: 30-3.
146. World Health Organization. Guidelines for the treatment of malaria, second edition. http://www.who.int/malaria/publications/atoz/9789241547925/en/i ndex html 2010.
147. Markus MB. Dormancy in mammalian malaria. Trends Parasitol 2012; 28: 39-45.
148. Treiber M, Wernsdorfer G, Wiedermann U, Congpuong K, Sirichaisinthop J, Wernsdorfer WH. Sensitivity of Plasmodium vivax to chloroquine, mefloquine, artemisinin and atovaquone in northwestern Thailand. Wien Klin Wochenschr 2011.
149. Rijken MJ, Boel ME, Russell B, et al. Chloroquine resistant vivax malaria in a pregnant woman on the western border of Thailand. Malar J 2011; 10: 113.
150. Baird JK. Resistance to chloroquine unhinges vivax malaria therapeutics. Antimicrob Agents Chemother 2011; 55: 1827-30.
151. Yohannes AM, Teklehaimanot A, Bergqvist Y, Ringwald P. Confirmed vivax resistance to chloroquine and effectiveness of artemether-lumefantrine for the treatment of vivax malaria in Ethiopia. Am J Trop Med Hyg 2011; 84: 137-40.
152. Sutanto I, Endawati D, Ling LH, Laihad F, Setiabudy R, Baird JK. Evaluation of chloroquine therapy for vivax and falciparum malaria in southern Sumatra, western Indonesia. Malar J 2010; 9: 52.
153. Nomura T, Carlton JM, Baird JK, et al. Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. J Infect Dis 2001; 183: 1653-61.
154. Orjuela-Sanchez P, de Santana Filho FS, Hado-Lima A, et al. Analysis of single-nucleotide polymorphisms in the crt-o and mdr1 genes of Plasmodium vivax among chloroquine-resistant isolates from the Brazilian Amazon region. Antimicrob Agents Chemother 2009; 53: 3561-4.
155. Huang F, Zhou S, Zhang S, Li W, Zhang H. Monitoring resistance of Plasmdium vivax: point mutations in dihydrofolate reductase gene in isolates from Central China. Parasit Vectors 2011; 4: 80.
156. Prajapati SK, Joshi H, Dev V, Dua VK. Molecular epidemiology of Plasmodium vivax anti-folate resistance in India. Malar J 2011; 10: 102.
157. Zakeri S, Afsharpad M, Ghasemi F, et al. Plasmodium vivax: prevalence of mutations associated with sulfadoxinepyrimethamine resistance in Plasmodium vivax clinical isolates from Pakistan. Exp Parasitol 2011; 127: 167-72.
158. Miao M, Yang Z, Cui L, Ahlum J, Huang Y, Cui L. Different allele prevalence in the dihydrofolate reductase and dihydropteroate synthase genes in Plasmodium vivax populations from China. Am J Trop Med Hyg 2010; 83: 1206-11.
159. Lu F, Lim CS, Nam DH, et al. Mutations in the antifolateresistance-associated genes dihydrofolate reductase and dihydropteroate synthase in Plasmodium vivax isolates from malariaendemic countries. Am J Trop Med Hyg 2010; 83: 474-9.
160. Watkins B, Sibley C. Vivax malaria: old drug, new uses? J Infect Dis 2011; 203: 144-5.
161. Imwong M, Russell B, Suwanarusk R, et al. Methotrexate is highly potent against pyrimethamine-resistant Plasmodium vivax. J Infect Dis 2011; 203: 207-10.
162. Chilengi R, Juma R, Abdallah AM, et al. A phase I trial to evaluate the safety and pharmacokinetics of low-dose methotrexate as an anti-malarial drug in Kenyan adult healthy volunteers. Malar J 2011; 10: 63.
163. Dar O, Khan MS, Adagu I. The potential use of methotrexate in the treatment of falciparum malaria: in vitro assays against sensitive and multidrug-resistant falciparum strains. Jpn J Infect Dis 2008; 61: 210-1.
164. Nduati E, Diriye A, Ommeh S, et al. Effect of folate derivatives on the activity of antifolate drugs used against malaria and cancer. Parasitol Res 2008; 102: 1227-34.
165. Anderson T, Nkhoma S, Ecker A, Fidock D. How can we identify parasite genes that underlie antimalarial drug resistance? Pharmacogenomics 2011; 12: 59-85.
166. Campino S, Auburn S, Kivinen K, et al. Population genetic analysis of Plasmodium falciparum parasites using a customized Illumina GoldenGate genotyping assay. PLoS One 2011; 6: e20251.
167. Hastings IM, Nsanzabana C, Smith TA. A comparison of methods to detect and quantify the markers of antimalarial drug resistance. Am J Trop Med Hyg 2010; 83: 489-95.
168. Hayton K, Su XZ. Drug resistance and genetic mapping in Plasmodium falciparum. Curr Genet 2008; 54: 223-39.
169. Crameri A, Marfurt J, Mugittu K, et al. Rapid microarray-based method for monitoring of all currently known single-nucleotide polymorphisms associated with parasite resistance to antimalaria drugs. J Clin Microbiol 2007; 45: 3685-91.
170. Use of high-density tiling microarrays to identify mutations globally and elucidate mechanisms of drug resistance in Plasmodium falciparum. Genome Biol 2009; 10: R21.
171. Steenkeste N, Dillies MA, Khim N, et al. FlexiChip package: an universal microarray with a dedicated analysis software for highthoughput SNPs detection linked to anti-malarial drug resistance. Malar J 2009; 8: 229.
172. Robinson T, Campino SG, Auburn S, et al. Drug-resistant genotypes and multi-clonality in Plasmodium falciparum analysed by direct genome sequencing from peripheral blood of malaria patients. PLoS One 2011; 6: e23204.
173. Yuan J, Cheng KC, Johnson RL, et al. Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. Science 2011; 333: 724-9.
174. Mu J, Myers RA, Jiang H, Liu S, et al. Plasmodium falciparum genome-wide scans for positive selection, recombination hot spots and resistance to antimalarial drugs. Nat Genet 2010; 42: 268-71.
175. Chiodini PL, Conlon CP, Hutchinson DB, Farquhar JA, Hall AP, Peto TE, et al. Evaluation of atovaquone in the treatment of patients with uncomplicated Plasmodium falciparum malaria. J Antimicrob Chemother 1995; 36: 1073-8.
176. Looareesuwan S, Viravan C, Webster HK, Kyle DE, Hutchinson DB, Canfield CJ. Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg 1996; 54: 62-6.
177. Nakato H, Vivancos R, Hunter PR. A systematic review and metaanalysis of the effectiveness and safety of atovaquone proguanil (Malarone) for chemoprophylaxis against malaria. J Antimicrob Chemother 2007; 60: 929-36.
178. Krudsood S, Patel SN, Tangpukdee N, et al. Efficacy of atovaquone-proguanil for treatment of acute multidrug-resistant Plasmo dium falciparum malaria in Thailand. Am J Trop Med Hyg 2007; 76: 655-8.
179. Sanz LM, Jimenez-Diaz MB, Crespo B, et al. Cyclopropyl carboxamides, a chemically novel class of antimalarial agents identified in a phenotypic screen. Antimicrob Agents Chemother 2011; 55: 5740-5.
180. Gille L, Nohl H. The ubiquinol/bc1 redox couple regulates mitochondrial oxygen radical formation. Arch Biochem Biophys 2001; 388: 34-8.
181. Peters W. The chemotherapy of rodent malaria. LVII. Drug combinations to impede the selection of drug resistance, Part 1: Which model is appropriate? Ann Trop Med Parasitol 1999; 93: 569-87.
182. Stewart LB, Peters W, Robinson BL. The chemotherapy of rodent malaria. LXII. Drug combinations to impede the selection of drug resistance, part 5: rates of development of resistance to some inhibitors of folate metabolism and to artesunate. Ann Trop Med Parasitol 2004; 98: 763-83.
183. Wang H, Bei ZC, Wang JY, Cao WC. Plasmodium berghei K173: selection of resistance to naphthoquine in a mouse model. Exp Parasitol 2011; 127: 436-9.
184. Tripathi R, Dhawan S, Dutta GP. Blood schizontocidal activity of azithromycin and its combination with alpha/beta arteether against multi-drug resistant Plasmodium yoelii nigeriensis, a novel MDR parasite model for antimalarial screening. Parasitology 2005; 131: 295-301.
185. Jimenez-Diaz MB, Mulet T, Viera S, et al. Improved murine model of malaria using Plasmodium falciparum competent strains and non-myelodepleted NOD-scid IL2Rgammanull mice engrafted with human erythrocytes. Antimicrob Agents Chemother 2009; 53: 4533-6.
186. Saralamba S, Pan-Ngum W, Maude RJ, et al. Intrahost modeling of artemisinin resistance in Plasmodium falciparum. Proc Natl Acad Sci U S A 2011; 108: 397-402.
187. Wein S, Maynadier M, Tran Van BC, et al. Reliability of antimalarial sensitivity tests depends on drug mechanisms of action. J Clin Microbiol 2010; 48: 1651-60.
188. Alonso PL, Brown G, Revalo-Herrera M, et al. A research agenda to underpin malaria eradication. PLoS Med 2011; 8: e1000406.
189. Bahamontes-Rosa N, Rodriguez-Alejandre A, Gonzalez-del-Rio R, Garcia-Bustos JF, Mendoza-Losana A. A new molecular approach for cidal vs static antimalarial determination by quantifying mRNA levels. Mol Biochem Parasitol 2012; 181: 171-7.
190. Sanz LM, Crespo B, De-Cozar C, et al. P. falciparum In vitro Killing Rates Allow to Discriminate between Different Antimalarial Mode-of-Action. PLoS One 2012; 7: e30949.